Bipolar disorder: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• GLP-1 0
• BDNF 0
• NMDA 1
• SGLT2 1
• PI3K 0
• AQP4 0
• PCSK9 0
• PPAR 0
• TNF 0
• AKT 0
• BRD4 0
• G6PD 0
• IGF1R 0
• IL-1 0
• IL-17 0
• IL-6 0
• MAPT 0
• NLRP3 0
• NRF2 0
• SIRT1 0
• TFEB 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIA · R01

  Proof of Concept (Phase 0) Study of Clinical Trial Outcomes and Biomarkers in Early Stage Dementia with Lewy Bodies

  University of Miami School of Medicine· Coral Gables, United States· US$644,011 awarded in fiscal year 2026· until May 2031

• NIH NIAAA · R01

  N-acetylcysteine for restoring glutamate/glutathione homeostasis and reducing heavy drinking in co-occurring bipolar and alcohol use disorders

  Medical University of South Carolina· Charleston, United States· US$674,482 awarded in fiscal year 2026· until Aug 2031

• NIH NIMH · R56

  Certified Older Adult Peer Support Specialists Telephonic Intervention to Support Independent Living Skills in Older Adults with Serious Mental Illness

  Dartmouth-Hitchcock Clinic· Lebanon, United States· US$1,133,543 awarded in fiscal year 2026· until Sept 2027

• NIH NCCIH · R01

  CRCNS: Dynamics of inter-area interactions during sleep and psychedelic states

  Princeton University· Princeton, United States· US$410,000 awarded in fiscal year 2026· until Jun 2031

• NIH NIMH · K23

  Integrating patient navigation with psychiatric care to increase use of HIV pre-exposure prophylaxis (PrEP) among young adults with severe mental illness

  Albert Einstein College of Medicine· Bronx, United States· US$199,584 awarded in fiscal year 2026· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-ERC

  The cerebellum: a transdiagnostic personalised target for neuromodulation in psychiatry (CLOVIS)

  Universite Paris Xii Val de Marne· Creteil, France· EU contribution €1,499,500· until Aug 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Callyope Copilot: Speech Foundation Model for Transdiagnostic Mental Health Assessment & Relapse Mitigation (CALLYOPECOPILOT)

  Callyope· Neuilly sur Seine, France· EU contribution €2,498,053· until May 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Personalized Genetic Risk Profile: A New Tool to Guide Prevention of Serious Mental Illness (PersonalRiskProfile)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €1,499,891· until Dec 2030

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Synaptic signatures: Understanding thalamocortical circuit specification and disease vulnerability (ThalamoLinkIT)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution €200,400· until Mar 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Synapsing Mental Disorders and Neurodegenerative diseases: Towards more effective diagnosis and management of psychiatric symptoms (SYNAPSING)

  Institut de Recerca de L'hospital de la Santa Creu I Sant Pau Fundacion· Barcelona, Spain· EU contribution €6,999,922· until Dec 2029· 9 countries

10 of 287 running projects, newest first. Listed amounts together: US$169.1m + €29.5m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 52
• CRISPR-Cas Systems 2
• Gene Expression Profiling 23
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 3
• Proteomics 17
• Metabolomics 8
• Mass Spectrometry 3
• Immunohistochemistry 1
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 190
• Machine Learning 59
• Deep Learning 9
• Cohort Studies 96
• Genome-Wide Association Study 107

• Association of Polygenic Risk Score for Suicidal Behavior With Ventral Prefrontal Morphology in Bipolar Disorder.

  Bipolar Disord, Nov 2026

• Neural Markers of Reward Valuation and Impulsive Decision-Making in Mania Risk.

  JAMA Psychiatry, Nov 2026

• Examinations of the heterogeneity in the structural brain connectome in schizophrenia.

  Psychol Med, Oct 2026

• Accelerated brain aging as a transdiagnostic biomarker: A lifespan MRI brain age study across seven disorders.

  Psychol Med, Oct 2026

• Loneliness as a risk factor for bipolar disorder and its related brain structure alterations.

  Psychol Med, Oct 2026

• Superposition of distinct psychotic and affective axes explains affective psychosis: evidence from cross-diagnostic connectomics.

  Prog Neuropsychopharmacol Biol Psychiatry, Sept 2026

• Neuroimaging Biomarkers for Brain Disorder Diagnosis Using Advanced Learning Techniques.

  Int J Neural Syst, Sept 2026

• Cerebral perfusion alterations are associated with clinical phenotypes and biotypes across the psychosis spectrum.

  Psychol Med, Sept 2026

• Revisiting the link between childhood adversity and stress-sensitive brain regions in psychosis and bipolar disorder: a systematic review and meta-analysis.

  Transl Psychiatry, Sept 2026

• Distinct brain functional patterns across the entire disease course between bipolar disorder and major depressive disorder: A Gaussian mixture model analysis.

  J Affect Disord, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.